{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:39Z","timestamp":1794047499239,"version":"4.8.0"},"reference-count":45,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"11","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>The multi-center randomized phase III NHL-004 study compared etoposide, dexamethasone and pegaspargase (ESA) versus the methotrexate, etoposide, dexamethasone and pegaspargase (MESA) regimen, combined with sandwiched radiotherapy, in newly diagnosed early-stage nasal natural killer \/ T-cell lymphoma (NKTCL). Here we report the long-term outcomes (median follow-up, 64 months) and biomarker analysis. A total of 256 eligible patients aged 14-70 years were randomly assigned (1:1) to the ESA or the MESA arm. The 5-year progression-free survival (PFS) rates were 80.3% and 74.9% in the ESA and MESA arms (hazard ratio [HR]=0.78 [95% CI: 0.46-1.33], P=0.371), and the 5-year overall survival (OS) rates were 85.1% and 80.9% (HR=0.74 [95% CI: 0.40-1.37], P=0.332), respectively. No new safety signals related to treatments were observed. Interim plasma Epstein-Barr virus (EBV) DNA positivity and stable disease \/ progressive disease response were independent predictors of inferior PFS and OS. No prognostic significance was observed according to molecular subtypes. Interim EBV DNA positivity correlated with up-regulated chromatin remodeling alterations, immune escape-related genes, and decreased infiltrating monocytes \/ M1 macrophages. With low toxicity, non-intravenous administration, and an outpatient design, ESA with sandwiched radiotherapy achieved long-term durable response in patients with newly diagnosed early-stage NKTCL. Dynamic monitoring of plasma EBV DNA provided a clinical rationale for future mechanism-based therapy in NKTCL.<\/jats:p>","DOI":"10.3324\/haematol.2025.287513","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T05:14:28Z","timestamp":1744262068000},"page":"2714-2725","source":"Crossref","is-referenced-by-count":6,"title":["Dynamic change in Epstein-Barr virus DNA predicts prognosis in early stage natural killer\/T-cell lymphoma with pegaspargase-based treatment: long-term follow-up and biomarker analysis from the NHL-004 multicenter randomized study"],"prefix":"10.3324","volume":"110","author":[{"given":"Huijuan","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongji","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoxu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohui","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juying","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanhua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianda","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongyang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ou","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zunmin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xufeng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaofu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binshen","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luqun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengpeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saijuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"81528","doi-asserted-by":"crossref","unstructured":"Yang Y, Zhu Y, Cao JZ. Risk-adapted therapy for early-stage extranodal nasal-type NK\/T-cell lymphoma: analysis from a multicenter study. Blood. 2015; 126(12):1424-1432.","DOI":"10.1182\/blood-2015-04-639336"},{"key":"81529","doi-asserted-by":"crossref","unstructured":"Qi SN, Yang Y, Zhang YJ. Risk-based, response-adapted therapy for early-stage extranodal nasal-type NK\/T-cell lymphoma in the modern chemotherapy era: a China Lymphoma Collaborative Group study. Am J Hematol. 2020; 95(9):1047-1056.","DOI":"10.1002\/ajh.25878"},{"key":"81530","doi-asserted-by":"crossref","unstructured":"Yamaguchi M, Tobinai K, Oguchi M. Phase I\/II study of concurrent chemoradiotherapy for localized nasal natural killer\/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2009; 27(33):5594-5600.","DOI":"10.1200\/JCO.2009.23.8295"},{"key":"81531","doi-asserted-by":"crossref","unstructured":"Wang L, Wang ZH, Chen XQ. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE\/IIE extranodal natural killer\/T-cell lymphoma. Cancer. 2013; 119(2):348-355.","DOI":"10.1002\/cncr.27752"},{"key":"81532","doi-asserted-by":"crossref","unstructured":"Kim SJ, Yang DH, Kim JS. Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK\/T cell lymphoma: CISL08-01 phase II study. Ann Hematol. 2014; 93(11):1895-1901.","DOI":"10.1007\/s00277-014-2137-6"},{"key":"81533","doi-asserted-by":"crossref","unstructured":"Wang L, Wang ZH, Chen XQ, Wang KF, Huang HQ, Xia ZJ. First-line combination of GELOX followed by radiation therapy for patients with stage IE\/IIE ENKTL: an updated analysis with long-term follow-up. Oncol Lett. 2015; 10(2):1036-1040.","DOI":"10.3892\/ol.2015.3327"},{"key":"81534","doi-asserted-by":"crossref","unstructured":"Yamaguchi M, Suzuki R, Oguchi M. Treatments and outcomes of patients with extranodal natural killer\/T-cell lymphoma diagnosed between 2000 and 2013: a cooperative study in Japan. J Clin Oncol. 2017; 35(1):32-39.","DOI":"10.1200\/JCO.2016.68.1619"},{"key":"81535","doi-asserted-by":"crossref","unstructured":"Zhang Y, Ma S, Cai J. Sequential P-GEMOX and radiotherapy for early-stage extranodal natural killer\/T-cell lymphoma: a multicenter study. Am J Hematol. 2021; 96(11):1481-1490.","DOI":"10.1002\/ajh.26335"},{"key":"81536","doi-asserted-by":"crossref","unstructured":"Wang X, Zhang L, Liu X. Efficacy and safety of a pegasparaginase-based chemotherapy regimen vs an L-asparaginase-based chemotherapy regimen for newly diagnosed advanced extranodal natural killer\/T-cell lymphoma: a randomized clinical trial. JAMA Oncol. 2022; 8(7):1035-1041.","DOI":"10.1001\/jamaoncol.2022.1968"},{"key":"81537","doi-asserted-by":"crossref","unstructured":"Xiong J, Cui BW, Wang N. Genomic and transcriptomic characterization of natural killer T cell lymphoma. Cancer Cell. 2020; 37(3):403-419.","DOI":"10.1016\/j.ccell.2020.02.005"},{"key":"81538","doi-asserted-by":"crossref","unstructured":"Xiong J, Dai YT, Wang WF. GPCR signaling contributes to immune characteristics of microenvironment and process of EBV-induced lymphomagenesis. Sci Bull (Beijing). 2023; 68(21):2607-2619.","DOI":"10.1016\/j.scib.2023.09.029"},{"key":"81539","doi-asserted-by":"crossref","unstructured":"Zhong H, Cheng S, Zhang X. Etoposide, dexamethasone, and pegaspargase with sandwiched radiotherapy in early-stage natural killer\/T-cell lymphoma: a randomized phase III study. Innovation (Camb). 2023; 4(3):100426.","DOI":"10.1016\/j.xinn.2023.100426"},{"key":"81540","doi-asserted-by":"crossref","unstructured":"Yahalom J, Illidge T, Specht L. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2015; 92(1):11-31.","DOI":"10.1016\/j.ijrobp.2015.01.009"},{"key":"81541","doi-asserted-by":"crossref","unstructured":"Cheson BD, Fisher RI, Barrington SF. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27):3059-3068.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"81542","doi-asserted-by":"crossref","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors P. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993; 329(14):987-994.","DOI":"10.1056\/NEJM199309303291402"},{"key":"81543","doi-asserted-by":"crossref","unstructured":"Kim SJ, Yoon DH, Jaccard A. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016; 17(3):389-400.","DOI":"10.1016\/S1470-2045(15)00533-1"},{"key":"81544","doi-asserted-by":"crossref","unstructured":"Hong H, Li Y, Lim ST. A proposal for a new staging system for extranodal natural killer T-cell lymphoma: a multicenter study from China and Asia Lymphoma Study Group. Leukemia. 2020; 34(8):2243-2248.","DOI":"10.1038\/s41375-020-0740-1"},{"key":"81545","doi-asserted-by":"crossref","unstructured":"Chen SY, Yang Y, Qi SN. Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK\/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making. Leukemia. 2021; 35(1):130-142.","DOI":"10.1038\/s41375-020-0791-3"},{"key":"81546","doi-asserted-by":"crossref","unstructured":"Wang ZY, Liu QF, Wang H. Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK\/T-cell lymphoma patients receiving primary radiotherapy. Blood. 2012; 120(10):2003-2010.","DOI":"10.1182\/blood-2012-06-435024"},{"key":"81547","doi-asserted-by":"crossref","unstructured":"Kwong YL, Pang AW, Leung AY, Chim CS, Tse E. Quantification of circulating Epstein-Barr virus DNA in NK\/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance. Leukemia. 2014; 28(4):865-870.","DOI":"10.1038\/leu.2013.212"},{"key":"81548","doi-asserted-by":"crossref","unstructured":"Yamaguchi M, Suzuki R, Kim SJ. Early disease progression in patients with localized natural killer\/T-cell lymphoma treated with concurrent chemoradiotherapy. Cancer Sci. 2018; 109(6):2056-2062.","DOI":"10.1111\/cas.13597"},{"key":"81549","doi-asserted-by":"crossref","unstructured":"Li PF, Mao YZ, Bai B. Persistent peripheral blood EBV-DNA positive with high expression of PD-L1 and upregulation of CD4 + CD25 + T cell ratio in early stage NK\/T cell lymphoma patients may predict worse outcome. Ann Hematol. 2018; 97(12):2381-2389.","DOI":"10.1007\/s00277-018-3467-6"},{"key":"81550","doi-asserted-by":"crossref","unstructured":"Kim SJ, Choi JY, Hyun SH. Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer\/T-cell lymphoma, nasal type: a multicentre, retrospective analysis. Lancet Haematol. 2015; 2(2):e66-74.","DOI":"10.1016\/S2352-3026(15)00002-2"},{"key":"81551","doi-asserted-by":"crossref","unstructured":"Suzuki R, Yamaguchi M, Izutsu K. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK\/T-cell lymphoma, nasal type. Blood. 2011; 118(23):6018-6022.","DOI":"10.1182\/blood-2011-05-354142"},{"key":"81552","doi-asserted-by":"crossref","unstructured":"Munz C. Latency and lytic replication in Epstein-Barr virus-associated oncogenesis. Nat Rev Microbiol. 2019; 17(11):691-700.","DOI":"10.1038\/s41579-019-0249-7"},{"key":"81553","doi-asserted-by":"crossref","unstructured":"Alsaadawe M, Radman BA, Long J, Alsaadawi M, Fang W, Lyu X. Epstein Barr virus: a cellular hijacker in cancer. Biochim Biophys Acta Rev Cancer. 2024; 1879(6):189218.","DOI":"10.1016\/j.bbcan.2024.189218"},{"key":"81554","doi-asserted-by":"crossref","unstructured":"Xiong J, Zhao WL. Advances in multiple omics of natural-killer\/T cell lymphoma. J Hematol Oncol. 2018; 11(1):134.","DOI":"10.1186\/s13045-018-0678-1"},{"key":"81555","doi-asserted-by":"crossref","unstructured":"Tian XP, Cao Y, Cai J. Novel target and treatment agents for natural killer\/T-cell lymphoma. J Hematol Oncol. 2023; 16(1):78.","DOI":"10.1186\/s13045-023-01483-9"},{"key":"81556","doi-asserted-by":"crossref","unstructured":"Morin RD, Mendez-Lago M, Mungall AJ. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011; 476(7360):298-303.","DOI":"10.1038\/nature10351"},{"key":"81557","doi-asserted-by":"crossref","unstructured":"Hoang NM, Rui L. DNA methyltransferases in hematological malignancies. J Genet Genomics. 2020; 47(7):361-372.","DOI":"10.1016\/j.jgg.2020.04.006"},{"key":"81558","doi-asserted-by":"crossref","unstructured":"Nebbioso A, Tambaro FP, Dell\u2019Aversana C, Altucci L. Cancer epigenetics: moving forward. PLoS Genet. 2018; 14(6):e1007362.","DOI":"10.1371\/journal.pgen.1007362"},{"key":"81559","doi-asserted-by":"crossref","unstructured":"Cai JY, Xu TT, Wang Y. Histone deacetylase HDAC4 promotes the proliferation and invasion of glioma cells. Int J Oncol. 2018; 53(6):2758-2768.","DOI":"10.3892\/ijo.2018.4564"},{"key":"81560","doi-asserted-by":"crossref","unstructured":"Adrover JM, McDowell SAC, He XY, Quail DF, Egeblad M. NETworking with cancer: the bidirectional interplay between cancer and neutrophil extracellular traps. Cancer Cell. 2023; 41(3):505-526.","DOI":"10.1016\/j.ccell.2023.02.001"},{"key":"81561","doi-asserted-by":"crossref","unstructured":"Wang H, Kim SJ, Lei Y. Neutrophil extracellular traps in homeostasis and disease. Signal Transduct Target Ther. 2024; 9(1):235.","DOI":"10.1038\/s41392-024-01933-x"},{"key":"81562","doi-asserted-by":"crossref","unstructured":"Jabs WJ, Wagner HJ, Maurmann S, Hennig H, Kreft B. Inhibition of macrophage inflammatory protein-1 alpha production by Epstein-Barr virus. Blood. 2002; 99(5):1512-1516.","DOI":"10.1182\/blood.V99.5.1512"},{"key":"81563","doi-asserted-by":"crossref","unstructured":"Fang Q, Stehr AM, Naschberger E, Knopf J, Herrmann M, Sturzl M. No NETs no TIME: crosstalk between neutrophil extracellular traps and the tumor immune microenvironment. Front Immunol. 2022; 13:1075260.","DOI":"10.3389\/fimmu.2022.1075260"},{"key":"81564","doi-asserted-by":"crossref","unstructured":"Gao FY, Li XT, Xu K, Wang RT, Guan XX. c-MYC mediates the crosstalk between breast cancer cells and tumor microenvironment. Cell Commun Signal. 2023; 21(1):28.","DOI":"10.1186\/s12964-023-01043-1"},{"key":"81565","doi-asserted-by":"crossref","unstructured":"Chew GL, Campbell AE, De Neef E. DUX4 suppresses MHC Class I to promote cancer immune evasion and resistance to checkpoint blockade. Dev Cell. 2019; 50(5):658-671.e7.","DOI":"10.1016\/j.devcel.2019.06.011"},{"key":"81566","doi-asserted-by":"crossref","unstructured":"Neugebauer E, Bastidas-Quintero AM, Weidl D, Full F. Pioneer factors in viral infection. Front Immunol. 2023; 14:1286617.","DOI":"10.3389\/fimmu.2023.1286617"},{"key":"81567","doi-asserted-by":"crossref","unstructured":"Carnevale J, Shifrut E, Kale N. RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature. 2022; 609(7925):174-182.","DOI":"10.1038\/s41586-022-05126-w"},{"key":"81568","doi-asserted-by":"crossref","unstructured":"Shi Y, Dong M, Hong X. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015; 26(8):1766-1771.","DOI":"10.1093\/annonc\/mdv237"},{"key":"81569","doi-asserted-by":"crossref","unstructured":"Tang T, Martin P, Somasundaram N. Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer\/T-cell lymphoma. Haematologica. 2021; 106(12):3170-3175.","DOI":"10.3324\/haematol.2020.251454"},{"key":"81570","doi-asserted-by":"crossref","unstructured":"Tao R, Fan L, Song Y. Sintilimab for relapsed\/refractory extranodal NK\/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4). Signal Transduct Target Ther. 2021; 6(1):365.","DOI":"10.1038\/s41392-021-00768-0"},{"key":"81571","doi-asserted-by":"crossref","unstructured":"Song Y, Malpica L, Cai Q. Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study. Lancet Oncol. 2024; 25(1):117-125.","DOI":"10.1016\/S1470-2045(23)00589-2"},{"key":"81572","doi-asserted-by":"crossref","unstructured":"Tao R, Liu C, Zhang W, Zhu Y, Ma Y, Hao S. Selinexor with anti-PD-1 antibody as a potentially effective regimen for patients with natural killer\/T-cell lymphoma failing prior L-asparaginase and PD-1 blockade. Oncologist. 2024; 29(1):e90-e96.","DOI":"10.1093\/oncolo\/oyad241"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/12026\/78281","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12026\/78977","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12026\/78281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:08:31Z","timestamp":1794046111000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/12026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":45,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2025.287513","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,10]]}}}